

(Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.)

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

1

of

5

Complete if Known

| | |
|------------------------|--------------------|
| Application Number | 10/591,195 |
| Filing Date | September 29, 2006 |
| First Named Inventor | Liat Hayardeny |
| Art Unit | 1649 |
| Examiner Name | Kolker, Daniel E. |
| Attorney Docket Number | 68051-B-PCT-US/JPW |

U. S. PATENT DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Document Number | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
|--------------------|-----------------------|---|--------------------------------|--|---|
| | | Number-Kind Code ² (<i>if known</i>) | | | |
| /D.K./ | 1 | US- 5,800,808 | 09-01-1998 | Konfino, et al. | |
| | 2 | US- 5,981,589 | 11-09-1999 | Konfino, et al. | |
| | 3 | US- 6,048,898 | 04-11-2000 | Konfino, et al. | |
| | 4 | US- 6,054,430 | 04-25-2000 | Konfino, et al. | |
| | 5 | US- 6,214,791 | 04-10-2001 | Aron, et al. | |
| | 6 | US- 6,342,476 | 01-29-2002 | Konfino, et al. | |
| | 7 | US- 6,362,161 | 03-26-2002 | Konfino, et al. | |
| | 8 | US- 6,514,938 | 02-04-2003 | Gad, et al. | |
| | 9 | US- 6,620,847 | 09-16-2003 | Konfino, et al. | |
| | 10 | US- 6,800,285 | 10-05-2004 | Rodriguez | |
| | 11 | US- 6,800,287 | 10-05-2004 | Gad, et al. | |
| | 12 | US- 6,939,539 | 09-06-2005 | Konfino, et al. | |
| | 13 | US- 7,022,663 | 04-04-2006 | Gilbert, et al. | |
| | 14 | US- 7,033,582 | 04-25-2006 | Yong, et al. | |
| | 15 | US- 7,074,580 | 07-22-2006 | Gad, et al. | |
| | 16 | US- 7,163,802 B2 | 01-16-2007 | Gad, et al. | |
| | 17 | US- 7,199,098 | 04-03-2007 | Konfino, et al. | |
| | 18 | US- 7,279,172 | 10-09-2007 | Aharoni, et al. | |
| | 19 | US- 2003-0170729 A1 | 09-11-2003 | Klinger | |

FOREIGN PATENT DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Foreign Patent Document | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear | T ⁶ |
|--------------------|-----------------------|--|--------------------------------|--|---|----------------|
| | | Country Code ³ -Number ⁴ -Kind Code ⁵ (<i>if known</i>) | | | | |
| /D.K./ | 29 | WO 98/30227 | 07-16-1998 | Yeda Research and Development CO., LTD. | | |
| | 30 | WO 00/05250 | 02-03-2000 | Yeda Research and Development CO., LTD. | | |
| | 31 | WO 00/18794 | 04-06-2000 | Yeda Research and Development CO., LTD. | | |
| | 32 | WO 00/27417 | 05-18-2000 | Yeda Research and Development CO., LTD. | | |
| | 33 | WO 01/60392 | 08-23-2001 | Yeda Research and Development CO., LTD. | | |
| | 34 | WO 01/93828 | 12-13-2001 | Teva Pharmaceuticals Industries, LTD. | | |

| | |
|--------------------|-----------------|
| Examiner Signature | Date Considered |
|--------------------|-----------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. *Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Applicants: Liat Hayardeny, et al.
Filed: §371 national stage of PCT
International Application No.
PCT/US2005/007072, filed March 3,
2005
ExhibitA

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

Complete if Known**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

2

of

5

| | |
|------------------------|--------------------|
| Application Number | 10/591,195 |
| Filing Date | September 29, 2006 |
| First Named Inventor | Liat Hayardeny |
| Art Unit | 1649 |
| Examiner Name | Kolker, Daniel E. |
| Attorney Docket Number | 68051-B-PCT-US/JPW |

| U. S. PATENT DOCUMENTS | | | | | |
|------------------------|-----------------------|--|--------------------------------|--|---|
| Examiner Initials* | Cite No. ¹ | Document Number | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
| | | Number-Kind Code ³ (if known) | | | |
| /D.K./ | 20 | US- 2005-0170004 | 08-04-2005 | Rosenberger | |
| | 21 | US- 2006-0122113 | 06-08-2006 | Pinchasi, et al. | |
| | 22 | US- 2006-0172942 A1 | 08-03-2006 | Dolitzky | |
| | 23 | US- 2006-0052586 | 03-09-2006 | Dolitzky | |
| | 24 | US- 2007-0021341 A1 | 01-25-2007 | Sela, et al. | |
| | 25 | US- 2007-0021324 A1 | 01-25-2007 | Dolitzky, et al. | |
| | 26 | US- 2007-0048794 A1 | 03-01-2007 | Gad, et al. | |
| | 27 | US- 2007-0054857 | 03-08-2007 | Pinchasi, et al. | |
| ↓ | 28 | US- 11/590,338 | 10-30-2006 | Pinchasi, et al. | |
| | | US- | | | |

| FOREIGN PATENT DOCUMENTS | | | | | |
|--------------------------|-----------------------|---|--------------------------------|--|---|
| Examiner Initials* | Cite No. ¹ | Foreign Patent Document | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear |
| | | Country Code ³ Number ⁴ Kind Code ⁵ (if known) | | | |
| /D.K./ | 35 | WO 01/97846 | 12-27-2001 | Teva Pharmaceuticals Industries, LTD. | |
| ↓ | 36 | WO 03/048735 | 06-12-2003 | Teva Pharmaceuticals Industries, LTD. | |
| | 59 | WO 04/43995 | 05-27-2004 | APOTEX PHARMACHEM INC. | |
| | 60 | WO 06/50122 | 05-11-2006 | Sandoz AG | |
| ↓ | 61 | WO 08/06026 | 01-10-2008 | MOMENTA PHARMACEUTICALS, INC. | |

| | | |
|--------------------|--|-----------------|
| Examiner Signature | | Date Considered |
|--------------------|--|-----------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, 1200 MARSHALL STREET, STOP IDIB, ALEXANDRIA, VA 22313-1450.

TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|------------------------------|---|----|---|------------------------|--------------------|
| Substitute for form 1449/PTO | | | | Complete if Known | |
| | | | | Application Number | 10/591,195 |
| | | | | Filing Date | September 29, 2006 |
| | | | | First Named Inventor | Liat Hayardeny |
| | | | | Art Unit | 1649 |
| | | | | Examiner Name | Kolker, Daniel E. |
| Sheet | 3 | of | 5 | Attorney Docket Number | 68051-B-PCT-US/JPW |

| NON PATENT LITERATURE DOCUMENTS | | | | | |
|---------------------------------|-----------------------|---|--|--|--|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | | | |
| /D.K./ | 37 | Bornstein et al., "Treatment of MS with a Synthetic Polypeptide: Preliminary Results" Ann. Neurol., 1980, 8, 117 ABSTRACT | | | |
| /D.K./ | 38 | Bornstein et al., "Treatment of MS with synthetic polypeptide: preliminary results" Trans. Am. Neurol. Assoc., 1980, 105, 348-350 | | | |
| /D.K./ | 39 | Bornstein et al., "MS: Trial of a synthetic polypeptide" Ann. Neurol., 1982, 11, 317-319 | | | |
| /D.K./ | 40 | Bornstein et al., "Clinical trials of Copolymer 1 in MS" Ann. N.Y. Acad. Sci. (USA), 1984, 366-372 | | | |
| /D.K./ | 41 | Bornstein et al., "Clinical Trials of a synthetic polypeptide (Copolymer 1) for the treatment of MS" Immunol. & Clin. Aspects of MS, 1984, 144-150 | | | |
| /D.K./ | 42 | Bornstein et al., "MS: Clinical Trials of a Synthetic Polypeptide, Copolymer 1" Neurol., 1985, 35 (Suppl. 1), 103 ABSTRACT | | | |
| /D.K./ | 43 | Bornstein, "Cop 1 may be beneficial for patients with exacerbating remitting form of MS" Adv. Ther., 1987, 4, 206 ABSTRACT | | | |
| /D.K./ | 44 | Bornstein, et al., "A Pilot trial of Cop 1 in Exacerbating remitting MS" New Eng. J. Med., 1987, 317 (7), 408-414 | | | |
| /D.K./ | 45 | Bornstein, et al., "Clinical Experience with COP-1 in MS" Neurol., 1988, 38 (Suppl. 2.), 66-69 | | | |
| | 46 | Bornstein, et al., "Rationale for immunomodulating Therapies of MS" Neurol., 1988, 38 (Suppl. 2.), 80-81R | | | |

| | |
|--------------------|-----------------|
| Examiner Signature | Date Considered |
|--------------------|-----------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known

| | | | | | |
|------------------------------|---|----|---|--------------------------|--------------------|
| Substitute for form 1449/PTO | | | | Complete if Known | |
| | | | | Application Number | 10/591,195 |
| | | | | Filing Date | September 29, 2006 |
| | | | | First Named Inventor | Liat Hayardeny |
| | | | | Art Unit | 1649 |
| | | | | Examiner Name | Kolker, Daniel E. |
| Sheet | 4 | of | 5 | Attorney Docket Number | 68051-B-PCT-US/JPW |

NON PATENT LITERATURE DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
|--------------------|-----------------------|---|----------------|
| /D.K./ | 47 | Bornstein et al., "Pilot Trial of COP-1 in Chronic Progressive MS: Preliminary report" Intl. MS Conf. 1988, in Elsevier Sci. Publi. 1989, 225-232 | |
| /D.K./ | 48 | Bornstein et al., "Clinical Trials of Cop 1 in MS" Handbook of MS, 1990, 469-480 | |
| /D.K./ | 49 | Bornstein et al., "A Placebo-controlled, Double-Blind, Randomized Two-center, Pilot Trial of Cop 1 in Chronic Progressive MS" Neurol., 1991, 41, 533-539 | |
| | 50 | Bornstein et al., "Treatment of MS with Copolymer 1" Treatment of MS, Trial Design, 1992, 173-198US5,800,808 | |
| /D.K./ | 51 | Bornstein, "Clinical Experience: Hopeful Prospects in MS," Hosp Prac. (Off. Ed.) May 15, 1992 vol. 27 (No. 5) L135-138, 141-142, 145-158 | |
| /D.K./ | 52 | Kalkers et al., "The effect of the neuroprotective agent riluzole on MRI parameters in primary progressive multiple sclerosis: a pilot study" in Multiple Sclerosis, 2002, vol. 8, issue 6, pages 532-533 | |
| /D.K./ | 53 | Sela et al., "Glatiramer acetate in the treatment of multiple sclerosis" in Expert Opin. Pharmacother., 2001, vol.2, no.7, pages 1149-1165 | |
| /D.K./ | 54 | Copaxone® (glatiramer acetate injection), prescribing information, http://www.copaxone.com/pdf/PrescribingInformation.pdf No date | |
| /D.K./ | 55 | International Preliminary Report on Patentability issued by the International Bureau of WIPO dated December 24, 2007 in connection with International Application No. PCT/US2005/0007072 | |
| /D.K./ | 56 | PCT International Search Report issued November 30, 2007 for International Application Publication No. PCT/US2005/0007072 | |

| | |
|--------------------|-----------------|
| Examiner Signature | Date Considered |
|--------------------|-----------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|------------------------------|---|----|---|-------------------------------|--------------------|
| Substitute for form 1449/PTO | | | | Complete if Known | |
| | | | | Application Number | 10/591,195 |
| | | | | Filing Date | September 29, 2006 |
| | | | | First Named Inventor | Liat Hayardeny |
| | | | | Art Unit | 1649 |
| | | | | Examiner Name | Kolker, Daniel E. |
| Sheet | 5 | of | 5 | Attorney Docket Number | 68051-B-PCT-US/JPW |

| NON PATENT LITERATURE DOCUMENTS | | | | | | |
|--|-----------------------|---|--|--|--|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | | | | T ² |
| /D.K./ | 57 | Written Opinion of the International Searching Authority issued by the International Searching Authority (ISA/AU) on November 30, 2007 in connection with International Application No. PCT/US2005/0007072 | | | | |
| /D.K./ | 58 | "COPAXONE®" in <u>Physician's Desk Reference</u> , Medical Economics Co., Inc., Montvale, NJ, 2002, 3115 - 3118 | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |

| | | | |
|--------------------|-----------------|-----------------|------------|
| Examiner Signature | /Daniel Kolker/ | Date Considered | 08/18/2008 |
|--------------------|-----------------|-----------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.